Moving immunotherapy to earlier lines in NSCLC

Immunotherapy alone or with chemotherapy is currently the standard of care in non-small cell lung cancer (NSCLC), and has made inroads in adjuvant space, following results from the Phase III IMpower010 trial (NCT02486718) of atezolizumab. Nathan Pennell, MD, PhD, Cleveland Clinic, Cleveland, OH, discusses what role immunotherapy should play in the future. He argues they should be used in earlier settings, and not after patients who progress after existing therapies as in the Phase III PACIFIC trial (NCT02125461). Combining immunotherapy and radiation has also been investigated in the DETERRED (NCT02525757), NICOLAS (NCT02434081), and KEYNOTE-799 (NCT03631784) trials. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).